WO2005018502A1 - PLEATED COMPOSITE ePTFE/TEXTILE HYBRID COVERING - Google Patents
PLEATED COMPOSITE ePTFE/TEXTILE HYBRID COVERING Download PDFInfo
- Publication number
- WO2005018502A1 WO2005018502A1 PCT/US2004/027084 US2004027084W WO2005018502A1 WO 2005018502 A1 WO2005018502 A1 WO 2005018502A1 US 2004027084 W US2004027084 W US 2004027084W WO 2005018502 A1 WO2005018502 A1 WO 2005018502A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- layer
- eptfe
- tubular
- textile
- graft
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2/06—Blood vessels
- A61F2/07—Stent-grafts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2/06—Blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/16—Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
- A61L27/48—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with macromolecular fillers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/507—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials for artificial blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/048—Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/12—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L31/125—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
- A61L31/129—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix containing macromolecular fillers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/89—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure the wire-like elements comprising two or more adjacent rings flexibly connected by separate members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2/06—Blood vessels
- A61F2/07—Stent-grafts
- A61F2002/072—Encapsulated stents, e.g. wire or whole stent embedded in lining
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2/06—Blood vessels
- A61F2/07—Stent-grafts
- A61F2002/075—Stent-grafts the stent being loosely attached to the graft material, e.g. by stitching
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2230/0002—Two-dimensional shapes, e.g. cross-sections
- A61F2230/0028—Shapes in the form of latin or greek characters
- A61F2230/005—Rosette-shaped, e.g. star-shaped
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/31504—Composite [nonstructural laminate]
Definitions
- the present invention relates generally to a implantable prosthesis material and structure. More particularly, the present invention relates to a composite multilayer implantable material and structure having a textile layer, an expanded polytetrafluoroethylene layer (ePTFE) formed in a pleated configuration and an elastomeric bonding agent layer, which joins the textile and ePTFE layer to form an integral structure.
- ePTFE expanded polytetrafluoroethylene layer
- Implantable prostheses are commonly used in medical applications.
- One of the more common prosthetic structures is a tubular prosthesis which may be used as a vascular graft to replace or repair damaged or diseased blood vessel.
- vascular graft to replace or repair damaged or diseased blood vessel.
- it should be designed with characteristics which closely resemble that of the natural body lumen which it is repairing or replacing.
- One form of a conventional tubular prosthesis specifically used for vascular grafts includes a textile tubular structure formed by weaving, knitting, braiding or any non-woven textile technique processing synthetic fibers into a tubular configuration.
- Tubular textile structures have the advantage of being naturally porous, which allows desired tissue ingrowth and assimilation into the body. This porosity, which allows for ingrowth of surrounding tissue, must be balanced with fluid tightness to minimize leakage during the initial implantation stage. Attempts to control the porosity of the graft while providing a sufficient fluid barrier have focused on increasing the thickness of the textile structure, providing a tighter stitch construction and incorporating features such as velours to the graft structure.
- grafts require the application of a biodegradable natural coating, such as collagen or gelatin in order to render the graft blood tight. While grafts formed in this manner overcome certain disadvantages inherent in attempts to balance porosity and fluid tightness, these textile prostheses may exhibit certain undesirable characteristics. These characteristics may include an undesirable increase in the thickness of the tubular structure, which makes implantation more difficult. These textile tubes may also be subject to kinking, bending, twisting or collapsing during handling. Moreover, application of a coating may render the grafts less desirable to handle from a tactility point of view.
- a biodegradable natural coating such as collagen or gelatin
- a tubular graft may be formed by stretching and expanding PTFE into a structure referred to as expanded polytetrafluoroethylene (ePTFE). Tubes formed of ePTFE exhibit certain beneficial properties as compared with textile prostheses.
- the expanded PTFE tube has a unique structure defined by nodes interconnected by fibrils. The node and fibril structure defines micropores, which facilitate a desired degree of tissue ingrowth while remaining substantially fluid-tight. Tubes of ePTFE may be formed to be exceptionally thin and yet exhibit the requisite strength necessary to serve in the repair or replacement of a body lumen.
- ePTFE tubes facilitates ease of implantation and deployment with minimal adverse impact on the body. While exhibiting certain superior attributes, ePTFE tubes are not without certain disadvantages. Grafts formed of ePTFE tend to be relatively non-compliant as compared with textile grafts and natural vessels. Further, while exhibiting a high degree of tensile strength, ePTFE grafts are susceptible to tearing. Additionally, ePTFE grafts lack the suture compliance of coated textile grafts. This may cause undesirable bleeding at the suture hole. Thus, the ePTFE grafts lack many of the advantageous properties of certain textile grafts.
- vascular grafts in conjunction with support structures.
- support structures typically come in the form of stents, which are formed of metal or polymeric materials generally formed in a tubular structure and are used to hold a vein or artery open.
- Stents are well known in the art and may be self-expanding or radially expandable by balloon expansion. Examples of stent/graft configurations known in the art can be seen in U.S. Patent Nos. 5,700,285; 5,749,880; and 5,123,917, each of which are herein incorporated by reference.
- stent/graft configurations because the stent provides and ensures the patency of the prosthesis, while the vascular graft provides biocompatible properties in a vessel more suitable for blood to flow.
- support structures such as a stent can result in axial elongation and radial shrinkage of the graft material due to the stresses applied to the graft material by the support structure during the contraction and expansion of the support structure.
- conventional textile prostheses as well as ePTFE prostheses have acknowledged advantages and disadvantages. Neither of the conventional prosthetic materials exhibits fully all of the benefits desirable for use as a vascular prosthesis.
- the present invention provides a composite multi-layered implantable prosthetic material and structure, which may be used in various applications, especially vascular applications.
- the implantable structure of the present invention may include a pleated ePTFE-lined textile graft, a pleated ePTFE graft, covered with a textile covering.
- additional ePTFE layers may be combined with any of these embodiments.
- pleats are provided along the length of the implantable material and structure.
- the number and length of the pleated sections can vary to control the resultant axial elongation, plastic deformation, longitudinal foreshortening and radial shrinkage of the graft material due to the stresses applied to the graft material by the support structure during the contraction and expansion of the support structure.
- the composite multi-layered implantable structure of the present invention includes a first layer formed of a textile material and a second layer formed of expanded polytetrafluoroethylene (ePTFE) being layered in a pleated pattern having a porous microstructure defined by nodes interconnected by fibrils.
- An elastomeric bonding agent may be applied to the second layer and disposed within the pores of the microstructure for securing the first layer to the second layer.
- the composite multi-layered implantable structure of the present invention may have a first inner tubular layer and a second outer tubular layer, both formed of ePTFE having a porous microstructure defined by nodes interconnected by fibrils.
- the first and second layers of ePTFE also may have a support structure positioned therebetween.
- this support structure takes the form of a radially expandable member, preferably a stent.
- a third tubular layer formed of textile material may be circumferentially disposed exteriorly to the first and second layers, and an elastomeric bonding agent may be applied to the second layer of ePTFE or the textile layer, and disposed within the pores of the ePTFE microstructure when the layers are bonded together.
- the multi-layered implantable structure further comprises a fourth layer of textile material circumferentially disposed interior to said first and second ePTFE layer and bonded to the first ePTFE layer with the elastomeric bonding agent. It is contemplated to further secure additional layers either interior or exterior said composite structure.
- the first and second ePTFE layers are preferably pleated in the axial direction prior to the bonding step.
- the bonding agent may be selected from a group of materials including biocompatible elastomeric materials such as urethanes, silicones, isobutylene/styrene copolymers, block polymers, and combinations thereof.
- the tubular composite material and structure of the present invention may also be formed from appropriately layered sheets which can then be overlapped to form tubular structures.
- Bifurcated, tapered, conical, and stepped-diameter tubular structures may also be formed from the present invention.
- the layered sheets may be pleated after being formed into a tubular structure.
- the textile layer may be formed of various textiles including knits, weaves, stretch knits, braids, any non-woven processing techniques, and combinations thereof.
- Various biocompatible polymeric materials may be used to form the textile structures, including polyethylene terephthalate (PET), naphthalene dicarboxylate derivatives such as polyethylene naphthalate, polybutylene naphthalate, polytrimethylene naphthalate, trimethylenediol naphthalate, ePTFE, natural silk, polyethylene and polypropylene, among others.
- PET is a particularly desirable material for forming the textile layer.
- the bonding agent is applied in solution to one surface of the ePTFE layer, preferably by spray coating.
- the textile layer is then placed in contact with the coated surface of the ePTFE layer.
- the bonding agent may also be applied in powder form by any known techniques; e.g. electrostatic spray.
- the bonding agent may also be applied and activated by thermal and/or chemical processes well known in the art and may be disposed within the pores of the coated surface.
- the present invention also provides an ePTFE-lined textile graft.
- the lined textile graft includes a tubular textile substrate bonded using a biocompatible elastomeric material to a tubular liner of ePTFE.
- a coating of an elastomeric bonding agent may be applied to the surface of the ePTFE liner so that the bonding agent is present in the micropores thereof.
- the coated liner is then secured to the tubular textile structure via the elastomeric bonding agent.
- the liner and textile graft can each be made very thin and still maintain the advantages of both types of materials.
- the present invention further provides a textile-covered ePTFE graft.
- the tubular ePTFE graft structure includes micropores defined by nodes interconnected by fibrils.
- a coating of an elastomeric bonding agent is applied to the surface of the ePTFE tubular structure with the bonding agent being resident within the microporous structure thereof.
- a tubular textile structure is applied to the coated surface of the ePTFE tubular structure and secured thereto by the elastomeric bonding agent.
- the composite multi-layered implantable structures of the present invention are designed to take advantage of the inherent beneficial properties of the materials forming each of the layers.
- the textile layer provides for enhanced tissue ingrowth, high suture retention strength and longitudinal compliance for ease of implantation.
- the ePTFE layer provides the beneficial properties of sealing the textile layer without need for coating the textile layer with a sealant such as collagen.
- the sealing properties of the ePTFE layer allow the wall thickness of the textile layer to be minimized.
- the ePTFE layer exhibits enhanced thrombo-resistance upon implantation.
- the elastomeric bonding agent not only provides for an integral composite structure, but adds further puncture-sealing characteristics to the final prosthesis. Additionally, plastic deformation of the ePTFE layer is controlled by the pleated structure, therefore detrimental effects on the beneficial properties of the ePTFE are minimized.
- the implantable structure may be used in conjunction with radially-expandable members such as stents and other structures which are capable of maintaining patency of the implantable structure in a bodily vessel.
- a stent may be disposed between two ePTFE layers with the outer ePTFE layer being joined to a tubular textile structure via the elastomeric bonding agent.
- a textile reinforcement may be secured to the inner ePTFE layer via the elastomeric bonding agent, in addition to or in the alternative the outer tubular textile structure.
- Any stent construction known to those skilled in the art may be used, including self-expanding stents, as well as, balloon-expandable stents.
- a composite multilayer implantable material having a first inner tubular layer formed of expanded polytetrafluoroethyene having a porous microstructure defined by nodes interconnected by fibrils, wherein said first layer has a plurality of pleated folds, a second tubular layer formed of textile material circumferentially disposed exteriorly to said first layer; and having an elastomeric bonding agent applied to one of said first layer or second layer and disposed within the pores of said microstructure for securing said first layer to said second layer.
- a method for producing a graft having pleated regions along it length is provided.
- the method includes forming a textile ePTFE composite graft material by providing a first tubular ePTFE structure having a microporous structure of nodes interconnected by fibrils, providing a second tubular ePTFE structure having a microporous structure of nodes interconnected by fibrils, folding a plurality of pleats into said first tubular ePTFE structure and said second tubular ePTFE structure, providing a tubular textile structure, placing a tubular support structure circumferentially around said first ePTFE tubular structure, placing said second tubular ePTFE structure circumferentially around said tubular support structure, applying a coating of an elastomeric bonding graft to a surface of said second ePTFE structure or said textile structure; and securing said coated liner surface to said textile structure.
- additives such as drugs, growth-factors, anti-thrombogenic agents and the like may also be employed.
- Figure 1 shows a schematic cross-section, a portion of a composite multi-layered implantable structure of the present invention.
- Figures 2 shows a schematic cross-section of an embodiment of the present invention.
- Figures 3 shows a schematic cross-section of an embodiment of the present invention.
- Figure 4 shows a portion of a pleated composite multi-layered implantable structure of the present invention prior to stretching.
- Figure 5 shows a schematic cross-section of the preferred embodiment of the present invention.
- Figure 6 shows a portion of a pleated composite multi-layered implantable structure of the present invention after stretching.
- Figure 7 shows a schematic cross-section of the preferred embodiment of the present invention.
- Figure 8 is a flow chart exemplifying a process for preparing one of the structures of the present invention.
- Figure 9 is an illustration of a graft according to the present invention with varying pleat amplitude and frequency.
- FIG. 10 is an illustration of a stent-graft assembly according to the present invention for implantation within a body lumen.
- the present invention provides a composite implantable prosthesis material and structure, desirably a vascular prosthesis material includes two layers of ePTFE, typically surrounding a stent, and a layer of a textile material.
- the ePTFE stent/graft layers are secured together, with the textile layer, by an elastomeric bonding agent.
- the vascular prosthesis material and vascular prosthesis of the present invention may include an ePTFE- lined textile vascular graft, and a ePTFE vascular graft including a textile covering.
- the material 10 may be a portion of a graft, or any other implantable structure.
- the material 10 includes a first layer 12, which is formed of a textile material.
- the textile material 12 of the present invention may be formed from synthetic yarns that may be flat, shaped, twisted, textured, pre-shrunk or un-shrunk.
- the yarns are made from thermoplastic materials including, but not limited to, polyesters, polypropylenes, polyethylenes, polyurethanes, polynaphthalenes, polytetrafluoroethylenes and the like.
- the yarns may be of the multifilament, monofilament or spun types. In most vascular applications, multifilaments are preferred due to the increase in flexibility. Where enhanced crush resistance is desired, the use of monofilaments have been found to be effective. As is well known, the type and denier of the yarn chosen are selected in a manner which forms a pliable soft tissue prosthesis and, more particularly, a vascular structure have desirable properties.
- the material 10 further includes a second layer 14 formed of expanded polytetrafluoroethylene (ePTFE).
- the ePTFE layer 14 may be produced from the expansion of PTFE formed in a paste extrusion process.
- the PTFE extrusion may be expanded and sintered in a manner well known in the art to form ePTFE having a microporous structure defined by nodes interconnected by elongate fibrils.
- the distance between the nodes referred to as the internodal distance (IND)
- IND internodal distance
- the resulting process of expansion and sintering yields pores 18 within the structure of the ePTFE layer.
- the size of the pores are defined by the IND of the ePTFE layer.
- the ePTFE of the present invention may also be "ultrathin" ePTFE as described in commonly-owned applications, U.S. Serial Nos. 10/012,825 and 10/012,919, the disclosures of which are herein incorporated by reference.
- the composite material 10 of the present invention may further include a bonding agent 20 applied to one surface 19 of ePTFE layer 18.
- the bonding agent 20 is preferably applied in solution by a spray coating process. However, other processes may be employed to apply the bonding agent.
- the bonding agent may include various biocompatible, elastomeric bonding agents such as urethanes, styrene/isobutylene/styrene block copolymers (SIBS), silicones, and combinations thereof. Other similar materials are contemplated.
- the bonding agent may include polycarbonate urethanes identified by the trade name CORETHANE®. This urethane is provided as an adhesive solution with preferably 7.5% Corethane, 2.5, in dimethylacetamide (DMAc) solvent.
- elastomeric refers to a substance having the characteristic that it tends to resume an original shape after any deformation thereto, such as stretching, expanding, or compression. It also refers to a substance which has a non-rigid structure, or flexible characteristics in that it is not brittle, but rather has compliant characteristics contributing to its non-rigid nature.
- the polycarbonate urethane polymers particularly useful in the present invention are more fully described in U.S. Patent Nos. 5,133,742 and 5,229,431, which are incorporated in their entirety herein by reference. These polymers are particularly resistant to degradation in the body over time and exhibit exceptional resistance to cracking in vivo. These polymers are segmented polyurethanes which employ a combination of hard and soft segments to achieve their durability, biostability, flexibility and elastomeric properties.
- the polycarbonate urethanes useful in the present invention are prepared from the reaction of an aliphatic or aromatic polycarbonate macroglycol and a diisocyanate in the presence of a chain extender.
- Aliphatic polycarbonate macroglycols such as polyhexane carbonate macroglycols and aromatic diisocyanates such as methylene diisocyanate are most desired due to the increased biostability, higher intramolecular bond strength, enhanced heat stability and flex fatigue life, as compared to other materials.
- the polycarbonate urethanes particularly useful in the present invention are the reaction products of a macroglycol, a diisocyanate and a chain extender.
- Examples of typical aromatic polycarbonate macroglycols include those derived from phosgene and bisphenol A or by ester exchange between bisphenol A and diphenyl carbonate such as (4,4 '-dihydroxy-diphenyl-2,2 '-propane) shown below, wherein n is between about 1 and about 12.
- Typical aliphatic polycarbonates are formed by reacting cycloaliphatic or aliphatic diols with alkylene carbonates as shown by the general reaction below:
- R is cyclic or linear and has between about 1 and about 40 carbon atoms and wherein Rl is linear and has between about 1 and about 4 carbon atoms.
- Typical examples of aliphatic polycarbonate diols include the reaction products of 1 ,6-hexanediol with ethylene carbonate, 1 ,4-butanediol with propylene carbonate, 1,5- pentanediol with ethylene carbonate, cyclohexanedimethanol with ethylene carbonate and the like and mixtures of above such as diethyleneglycol and cyclohexanedimethanol with ethylene carbonate.
- polycarbonates such as these can be copolymerized with components such as hindered polyesters, for example phthalic acid, in order to form carbonate/ester copolymer macroglycols.
- Copolymers formed in this manner can be entirely aliphatic, entirely aromatic, or mixed aliphatic and aromatic.
- the polycarbonate macroglycols typically have a molecular weight of between about 200 and about 4000 Daltons.
- Diisocyanate reactants according to this invention have the general structure OCN-R'-
- R' is a hydrocarbon that may include aromatic or nonaromatic structures, including aliphatic and cycloaliphatic structures.
- exemplary isocyanates include the preferred methylene diisocyanate (MDI), or 4,4-methylene bisphenyl isocyanate, or 4,4'- diphenylmethane diisocyanate and hydrogenated methylene diisocyanate (HMDI).
- isocyanates include hexamethylene diisocyanate and other toluene diisocyanates such as 2,4-toluene diisocyanate and 2,6-toluene diisocyanate, 4,4' tolidine diisocyanate, m- phenylene diisocyanate, 4-chloro-l,3-phenylene diisocyanate, 4,4-tetramethylene diisocyanate, 1 ,6-hexamethylene diisocyanate, 1,10-decamethylene diisocyanate, 1,4- cyclohexylene diisocyanate, 4,4 '-methylene bis (cyclohexylisocyanate), 1 ,4-isophorone diisocyanate, 3,3'-dimethyl-4,4'-diphenylmethane diisocyanate, 1,5-tetrahydronaphthalene diisocyanate, and mixtures of such diisocyanates. Also included among the isocyanates,
- Suitable chain extenders included in this polymerization of the polycarbonate urethanes should have a functionality that is equal to or greater than two.
- a preferred and well-recognized chain extender is 1,4-butanediol.
- diols or diamines are suitable, including the ethylenediols, the propylenediols, ethylenediamine, 1,4- butanediamine methylene dianiline heteromolecules such as ethanolamine, reaction products of said diisocyanates with water and combinations of the above.
- the polycarbonate urethane polymers according to the present invention should be substantially devoid of any significant ether linkages (i.e., when y is 0, 1 or 2 as represented in the general formula hereinabove for a polycarbonate macroglycol), and it is believed that ether linkages should not be present at levels in excess of impurity or side reaction concentrations. While not wishing to be bound by any specific theory, it is presently believed that ether linkages account for much of the degradation that is experienced by polymers not in accordance with the present invention due to enzymes that are typically encountered in vivo, or otherwise, attack the ether linkage via oxidation. Live cells probably catalyze degradation of polymers containing linkages. The polycarbonate urethanes useful in the present invention avoid this problem.
- the quantity of macroglycol should be minimized to thereby reduce the number of ether linkages in the polycarbonate urethane.
- minimizing the polycarbonate soft segment necessitates proportionally increasing the chain extender hard segment in the three component polyurethane system. Therefore, the ratio of equivalents of chain extender to macroglycol should be as high as possible.
- the ratio of equivalents of chain extender to polycarbonate and the resultant hardness is a complex function that includes the chemical nature of the components of the urethane system and their relative proportions.
- the hardness is a function of the molecular weight of both chain extender segment and polycarbonate segment and the ratio of equivalents thereof.
- MDI 4,4'-methylene bisphenyl diisocyanate
- a 1 ,4-butanediol chain extender of molecular weight 90 and a polycarbonate urethane of molecular weight of approximately 2000 will require a ratio of equivalents of at least about 1.5 to 1 and no greater than about 12 to 1 to provide non-biodegrading polymers.
- the ratio should be at least about 2 to 1 and less than about 6 to 1.
- the preferred ration should be at least about 1 to 1 and no greater than about 3 to 1.
- a polycarbonate glycol having a molecular weight of about 500 would require a ratio in the range of about 1.2 to about 1.5:1.
- the lower range of the preferred ratio of chain extender to macroglycol typically yields polyurethanes of Shore 80A hardness.
- the upper range of ratios typically yields polycarbonate urethanes on the order of Shore 75D.
- the preferred elastomeric and biostable polycarbonate urethanes for most medical devices would have a Shore hardness of approximately 85A.
- Cross-linking can be controlled by avoiding an isocyanate-rich situation.
- the general relationship between the isocyanate groups and the total hydroxyl (and/or amine) groups of the reactants should be on the order of approximately 1 to 1.
- Cross-linking can be controlled by controlling the reaction temperatures and shading the molar ratios in a direction to be certain that the reactant charge is not isocyanate-rich; alternatively a termination reactant such as ethanol can be included in order to block excess isocyanate groups which could result in cross-linking which is greater than desired.
- the polycarbonate urethane polymers can be reacted in a single-stage reactant charge, or they can be reacted in multiple states, preferably in two stages, with or without a catalyst and heat.
- Other components such as antioxidants, extrusion agents and the like can be included, although typically there would be a tendency and preference to exclude such additional components when a medical-grade polymer is being prepared.
- the polycarbonate urethane polymers can be polymerized in suitable solvents, typically polar organic solvents in order to ensure a complete and homogeneous reaction.
- Solvents include dimethylacetamide, dimethylformamide, dimethylsulfoxide toluene, xylene, m-pyrrol, tetrahydrofuran, cyclohexanone, 2-pyrrolidone, and the like, or combinations thereof. These solvents can also be used to delivery the polymers to the ePTFE layer of the present invention.
- a particularly desirable polycarbonate urethane is the reaction product of polyhexamethylenecarbonate diol, with methylene bisphenyl diisocyanate and the chain extender 1,4-butanediol.
- the use of the elastomeric bonding agent in solution is particularly beneficial in that by coating the surface 19 of ePFTE layer 14, the bonding agent solution enters the pores 18 of layer 14 defined by the IND of the ePTFE layer.
- the ePTFE is a highly hydrophobic material, it is difficult to apply a bonding agent directly to the surface thereof.
- a bonding agent which may be disposed within the micropores of the ePFTE structure, enhanced bonding attachment between the bonding agent and the ePFTE surface is achieved.
- the bonding agents of the present invention are elastomeric materials which exhibit elastic properties.
- Conventional ePTFE is generally regarded as an inelastic material, i.e., even though it can be further stretched, it has little memory. Therefore, conventional ePTFE exhibits a relatively low degree of longitudinal compliance.
- suture holes placed in conventional ePTFE structures do not self-seal, due to the inelasticity of the ePTFE material.
- textile layer 12 is secured to surface 19 of ePTFE layer 14 which has been coated with bonding agent 20.
- the textile layer 12 is secured by placing it in contact with the bonding agent.
- this process can be performed either by mechanical, chemical, or thermal techniques or combinations thereof.
- the composite material 10 may be used in various vascular applications in planar form or in tubular form as a graft.
- the textile surface may be designed as a tissue contacting surface in order to promote enhanced cellular ingrowth which contributes to the long term patency of the prosthesis.
- the ePTFE surface 14 may be used as a blood contacting surface so as to minimize leakage and to provide a generally anti-thrombogetic surface. While this is the preferred usage of the composite prosthesis of the prevent invention, in certain situations, the layers may be reversed where indicated.
- the present invention provides for various embodiments of composite ePTFE/textile prosthesis.
- the composite ePTFE-lined textile graft is desirably formed as follows.
- a thin ePFTE tube is formed in a conventional forming process such as by tubular extrusion or by sheet extrusion where the sheet is formed into a tubular configuration.
- the ePTFE tube is placed over a stainless steel mandrel and the ends of the tube are secured.
- the ePTFE sheet or tube is pleated on the mandrel in a plurality of locations by folding the ePTFE layer over upon itself.
- the ePTFE tube is then spray coated with an adhesive solution of anywhere from 1% - 15% Corethane ® urethane, 2.5 in DMAc. As noted above, other adhesive solutions may also be employed.
- the coated ePTFE tube is placed in an oven heated in a range from 18°C to 150°C oven for 5 minutes to overnight to dry off the solution. If desired, the spray coating and drying process can be repeated multiple times to add more adhesive to the ePTFE tube.
- the pleated regions of the ePTFE layer effectively mask portions of the tubular layer, preventing the adhesive from covering all of the tubing.
- the coated ePTFE tube is then covered with the textile tube to form the composite prosthesis.
- One or more layers of elastic tubing, preferably silicone, is then placed over the composite structure. This holds the composite structure together and assures that complete contact and adequate pressure is maintained for bonding purposes.
- the assembly of the composite graft within the elastic tubing is placed in an oven and heated in a range of 180°-220°C for approximately 5-30 minutes to bond the layers together.
- the ePTFE lined textile graft may be crimped along the tubular surface thereof to impart longitudinal compliance, kink resistance and enhanced handling characteristics.
- the crimp may be provided by placing a coil of metal or plastic wire around a stainless steel mandrel. The graft is slid over the mandrel and the coil wire. Another coil is wrapped around the assembly over the graft to fit between the spaces of the inner coil. The assembly is then heat set and results in the formation of the desired crimp pattern. It is further contemplated that other conventional crimping processes may also be used to impart a crimp to the ePTFE textile graft.
- the graft can be wrapped with a polypropylene monofilament.
- This monofilament is wrapped in a helical configuration and adhered to the outer surface of the graft either by partially melting the monofilament to the graft or by use of an adhesive.
- the ePTFE-lined textile graft exhibits advantages over conventional textile grafts in that the ePTFE liner acts as a barrier membrane which results in less incidences of bleeding without the need to coat the textile graft in collagen.
- the wall thickness of the composite structure may be reduced while still maintaining the handling characteristics, especially where the graft is crimped. A reduction in suture hole bleeding is seen in that the elastic bonding agent used to bond the textile to the ePTFE, renders the ePTFE liner self-sealing.
- the process for forming the textile covered ePTFE vascular graft may be described as follows.
- An ePTFE tube formed preferably by tubular paste extrusion is placed over a stainless steel mandrel. After being placed on the mandrel, the ePTFE is pleated in a plurality of locations. The pleats are formed by folding the ePTFE layer over itself, creating a gathered section of ePTFE material. The gathered sections lengthen the amount of ePTFE material used to form the tube. After pleating, the ends of the ePTFE tube are secured.
- the ePTFE tube is coated using an adhesive solution of from 1% - 15% Corethane ® , 2.5 in DMAc.
- the coated ePTFE tubular structure is then placed in an oven heated in a range from 18°C to 150°C for 5 minutes to overnight to dry off the solution.
- the coating and drying process can be repeated multiple times to add more adhesive to the ePTFE tubular structure.
- the pleats are folded perpendicular to the axial length of the tube, such that longitudinal expansion of the graft device will cause the pleats to unfold.
- the ePTFE tubular structure may be longitudinally compressed in the axial direction to between 1% to 85% of its length to relax the fibrils of the ePTFE.
- the amount of desired compression may depend upon the amount of longitudinal expansion that was imparted to the base PTFE green tube to create the ePTFE tube. Longitudinal expansion and compression may be balanced to achieve the desired properties. This is done to enhance the longitudinal stretch properties of the resultant graft.
- the longitudinal compression process can be performed either by manual compression or by thermal compression.
- the number and length of the pleated regions of the ePTFE layer are additional factors that can be modified to alter the properties of the resultant graft.
- the compressed ePTFE tube is then covered with a thin layer of the textile tube.
- the assembly is then placed in a 205°C oven for approximately 10-20 minutes to bond the layers together.
- the composite graft can be wrapped with a polypropylene monofilament which is adhered to the outer surface by melting or use of an adhesive.
- the polypropylene monofilament will increase the crush and kink resistance of the graft.
- the graft can be crimped in a convention manner to yield a crimped graft.
- the textile covered ePTFE graft exhibits superior longitudinal strength as compared with conventional ePTFE vascular grafts.
- the composite structure maintains high suture retention strength and reduced suture hole bleeding. This is especially beneficial when used as a dialysis access graft in that the composite structure has increased strength and reduced puncture bleeding. This is achieved primarily by the use of an elastomeric bonding agent between the textile tubular structure and the ePTFE tubular structure in which the elastic bonding agent has a tendency to self-seal suture holes.
- a composite graft 60 is shown having a tubular support structure 62 interposed between inner and outer ePTFE layers 64 and 66.
- the ePTFE layers 64 and 66 are joined using any technique known to those skilled in the art, such as by sintering or with an adhesive (thermoplastic fluoropolymer adhesive (FEP)).
- FEP thermoplastic fluoropolymer adhesive
- the ePTFE layers 64, 66 are joined through interstices found in the support structure 62, preferably without being affixed to the support structure 62.
- the outer ePTFE layer 66 is bonded to a textile layer 68 with a layer of bonding agent 70.
- the arrangement of the layers may be altered, wherein the support structure 62 and the ePTFE layers 64, 66 may be disposed externally of the textile layer 68 with the layer of bonding agent 70 being interposed between the textile layer 68 and the inner ePTFE layer 64.
- the composite graft is formed to allow for simultaneous radial expansion of the support structure 62 along with the ePTFE layers 64, 66 and the textile layer 68. The radial expansion is preferably unhindered by any of the constituent elements of the composite graft.
- the tubular support structure 62 may be any structure known in the art, which is capable of maintaining patency of the composite graft 60 in a bodily vessel.
- the support structure 62 may be a stent, and preferably is radially expandable.
- Radially expandable member 62 may be of any stent configuration known to those skilled in the art, including those used alone or in a stent/graft arrangement.
- Various stent types and stent constructions may be employed in the present invention including, without limitation, self- expanding stents and balloon expandable stents.
- the stents may be capable of radially contracting as well.
- Self-expanding stents include those that have a spring-like action, which cause the stent to radially expand, or stents, which expand due to the memory properties of the stent material for a particular configuration at a certain temperature.
- Nitinol ® is an example of a material, which may be used as a self-expanding stent.
- Other materials are of course contemplated, such as stainless steel, platinum, gold, titanium, tantalum, niobium, and other biocompatible materials, as well as polymeric stents.
- the configuration of the stent may also be chosen from a host of geometries.
- wire stents can be fastened in a continuous helical pattern, with or without wave-like forms or zigzags in the wire, to form a radially deformable stent.
- Individual rings or circular members can be linked together such as by struts, sutures, or interlacing or locking of the rings to form a tubular stent.
- Figure 2 shows one particular distensible member 62, a stent, which may be employed in prosthesis 60.
- the particular stent shown in Figure 2 is more fully described in commonly assigned U.S. Patent No. 5,693,085 to Buirge et al. and the disclosure of U.S. Patent No. 5,693,085 is incorporated by reference herein.
- an alternative embodiment of the composite graft 60 according to the present invention is shown therein and designated generally with the reference numeral 60'. Like numbers are used to designate like elements.
- an additional inner textile reinforcement 72 is provided which is fixed by an inner layer of bonding agent 74.
- the textile layers 68, 72 and the bonding agent layers 70, 74 may be of any structure described in the embodiments above. Likewise, the interaction between the ePTFE layers, the textile layers, and the bonding agent 70, 74 is the same interaction described above.
- an implantable prosthesis may be formed which is self-supporting and usable to maintain patency of a bodily vessel, such as in the vasculature, esophagus, trachea, colon, biliary tract, urinary tract, prostate, and brain.
- the composite graft 60, 60' may be treated with any of the following: anti-thrombogenic agents (such as heparin, heparin derivatives, urokinase, and PPack (dextrophenylalanine proline arginine chloromethylketone); anti-proliferative agents (such as enoxaprin, angiopeptin, or monoclonal antibodies capable of blocking smooth muscle cell proliferation, hirudin, and acetylsalicylic acid); anti-inflammatory agents (such as dexamethasone, prednisolone, corticosterone, budesonide, estrogen, sulfasalazine, and mesalamine); antineoplastic/antiproliferative/anti-miotic agents (such as paclitaxel, 5-fluorouracil, cisplatin, vinblastine, vincristine, epothilones, endostatin, angiostatin and thymidine kinase inhibitor
- FIG. 4 a plan view of a pleated section of the composite graft material of the present invention is shown prior to stretching.
- the depicted section has a top surface 402, having a plurality of pleated regions 404 formed on the top surface of the graft material.
- the pleated regions are formed by folding the ePTFE material into a flap, which is flattened against the surface of the graft material.
- the flattened flap creates a region of triple layered ePTFE.
- the top layer of the ePTFE is covered by the adhesive for bonding the textile layer.
- Pleats are incorporated in the material of the present invention along the length of the graft in the manner shown in Figure 4 so as to control the resultant axial elongation, plastic deformation, longitudinal foreshortening and radial shrinkage of the graft material due to the stresses applied to the graft material by the support structure during the contraction and expansion of the support structure.
- the length and number of pleats can be varied along the length of the graft in accordance with the expected stress on the graft material from the support structure.
- Resultant axial elongation, plastic deformation, longitudinal foreshortening and radial shrinkage of the graft material can thus be limited by the application of longer pleats or a greater number of pleats along the length of the graft.
- Fig. 5 there is shown a cross section view, denoted as section A-A,
- the pleated ePTFE layer 502 an adhesive layer 504 and a textile layer 506.
- the pleat is formed of a gathered section of ePTFE that is folded substantially flat against the surface of the ePTFE.
- the surface of the pleated ePTFE layer 502 is coated with an adhesive 504, for bonding the textile layer 506 to the ePTFE layer 502.
- the pleat masks a portion of the ePTFE layer 508, and prevents the application of adhesive to that masked portion.
- the pleated portion can unfold independently of the textile and adhesive layer when the composite device is stretched. Some or all of the elongation produced by the stretching can thus be accommodated by the unfolding of the ePTFE layer. Any elongation in excess of the length added by the pleated regions will result in plastic deformation of the ePTFE layer. However, the plastic deformation can be controlled by varying the number and length of the pleated sections. Increasing the length of the ePTFE material gathered in the pleated sections or the number of pleats, will result in less plastic deformation of the completed device after stretching.
- the material of the present invention would be attached to a support structures.
- a support structures such as a stent, which are formed of metal or polymeric materials generally formed in a tubular structure and are used to hold a vein or artery open. Stents may be self- expanding or radially expandable by balloon expansion.
- a stent graft device is inserted into a delivery system such as a catheter for treatment of the patient. When the stent graft device is inserted into the delivery system it elongates and shrinks in diameter due to the stresses applied to by the stent. The pleated sections, allow the stretching of the ePTFE layer while reducing the plastic deformation of the device when it is stored in the catheter. The ePTFE is pleated to allow a pre-determined amount of dimensional loss to occur.
- FIG. 6 a plan view of a section of the composite graft material of the present invention is shown after stretching.
- the depicted section has a top surface 602, wherein the flaps of the pleated regions have been unfolded, thereby lengthening the graft material section depicted.
- FIG. 7 there is shown a cross section view, denoted as section B-B, (as shown in Fig. 6) of the pleated material according to the present invention after stretching.
- the ePTFE layer 702 wherein the pleated section has been unfolded, an adhesive layer 704 and a textile layer 706.
- the masking of the ePTFE layer by the pleated region allows the excess material of the ePTFE layer 702 to unfold into parallel alignment with the textile layer during the stretching of the device.
- the plastic deformation of the ePTFE layer is therefore controlled by providing excess material that unfolds during stretching. Additionally, due to the excess length of ePTFE material prior to stretching, the percentage of plastic deformation that occurs during the stretching to that layer is reduced.
- FIG. 8 In an exemplary method of forming the composite graft 60, 60', flow chart 80 is presented in Figure 8.
- components of the composite graft 60, 60' are provided, including the support structure 62; the inner and outer ePTFE layers 64, 66; the textile reinforcement 68 (and, optionally, inner textile reinforcement layer 72); and, bonding agent to form layers 70 and/or 74.
- the ePTFE layers are pleated in a plurality of locations, step 84. The length and number of pleats are pre-determined based upon the desired amount of expected longitudinal extension.
- the support structure 62 is interposed between the first and second ePTFE layers 64, 66, for example, on a mandrill, step 86.
- the ePTFE layers 64 and 66 are sintered together, step 88, so as to bond through the interstices of the support structure 62.
- the textile layer 68, and, optionally, the textile reinforcement 72, are joined using the layers of bonding agents 70 and 74 in the same process described above with previous embodiments (step 89).
- Figure 9 shows several of many possible pleated grafts and graft material designs to illustrate that the length and number of the pleats may be varied in order to control the amount of possible longitudinal extension.
- exemplary graft material 902 having pleated regions 904, separated by non-pleated spaces 906, exemplary graft material 912, having pleated regions 914, separated by non-pleated spaces 916 and exemplary graft material 922, having pleated regions 924, separated by non-pleated spaces 926.
- the length of the pleated regions as well as the spacing between pleats can be varied.
- the material properties can be altered to suit the particular application.
- the length and number of the pleats may be varied depending on the desired characteristics for a specific graft application. As shown in Figure 9, several non-limiting variable pleat lengths and numbers are shown in accordance with the present invention. Either the length of pleats, number of pleats or both limitations in combination can control the amount of possible longitudinal extension of the graft.
- the frequency/length, i.e. number of pleats for a given length may vary, based upon the length of the device as well as the length of the pleats.
- the length of the pleats may typically be in the range of .5mm to 2mm.
- the distance between the pleats may typically be in the range of 5mm to 20mm.
- a stent-graft of the present invention at a preloaded stage for deployment into a vascular vessel.
- Stent 102 is disposed within and preferably attached to end portions 104 and/or 106 of graft 10.
- a stent 102 can alternatively be constructed as lining within a graft (not shown) extending from one end of the graft to the other to provide both fastening of the graft to the stent and additionally structural stability.
- the stent-graft 100 stretches longitudinally to provide an open lumen and maintains its flexibility.
- the pleats of the present graft unfold in response to the longitudinal forces produced by the stent device as it is opened, thereby reducing or eliminating the plastic deformation of the ePTFE layer.
- the graft- stent can be stretched in the axial direction to 175% of its length during loading and when released from the delivery system recover to 125% of it length.
- the overall length change is 25%).
- the material of the present invention does not interfere with the stretching of the textile layer, which is almost fully recoverable, while controlling the stretch of the ePTFE layer to a predetermined amount.
- the dimensional change of the device caused by the loading process during delivery can be reduced or eliminated.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20040781710 EP1663067A1 (en) | 2003-08-19 | 2004-08-19 | PLEATED COMPOSITE ePTFE/TEXTILE HYBRID COVERING |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/643,315 | 2003-08-19 | ||
US10/643,315 US7510571B2 (en) | 2001-06-11 | 2003-08-19 | Pleated composite ePTFE/textile hybrid covering |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005018502A1 true WO2005018502A1 (en) | 2005-03-03 |
Family
ID=34216379
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/027084 WO2005018502A1 (en) | 2003-08-19 | 2004-08-19 | PLEATED COMPOSITE ePTFE/TEXTILE HYBRID COVERING |
Country Status (3)
Country | Link |
---|---|
US (1) | US7510571B2 (US07510571-20090331-C00001.png) |
EP (1) | EP1663067A1 (US07510571-20090331-C00001.png) |
WO (1) | WO2005018502A1 (US07510571-20090331-C00001.png) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007002331A1 (en) * | 2005-06-23 | 2007-01-04 | Boston Scientific Scimed, Inc. | Eptfe lamination-resizing eptfe tubing |
DE102007008185A1 (de) * | 2007-02-13 | 2008-08-14 | Aesculap Ag & Co. Kg | Non woven Gefäßprothese und Verfahren zu ihrer Herstellung |
GB2429407B (en) * | 2005-06-04 | 2009-10-14 | Vascutek Ltd | Thin-walled vascular graft |
WO2011146733A1 (en) | 2010-05-20 | 2011-11-24 | Maquet Cardiovascular Llc | Composite prosthesis with external polymeric support structure and methods of manufacturing the same |
US20210260252A1 (en) * | 2011-10-07 | 2021-08-26 | W. L. Gore & Associates, Inc. | Puncturable and resealable graft |
CN115252900A (zh) * | 2017-10-31 | 2022-11-01 | 豪淘斯医疗有限公司 | 具有密封剂或覆层的纺织产品和制造方法 |
Families Citing this family (108)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6454799B1 (en) | 2000-04-06 | 2002-09-24 | Edwards Lifesciences Corporation | Minimally-invasive heart valves and methods of use |
CA2419811A1 (en) | 2000-08-18 | 2002-02-28 | Atritech, Inc. | Expandable implant devices for filtering blood flow from atrial appendages |
US7828833B2 (en) * | 2001-06-11 | 2010-11-09 | Boston Scientific Scimed, Inc. | Composite ePTFE/textile prosthesis |
US8308797B2 (en) | 2002-01-04 | 2012-11-13 | Colibri Heart Valve, LLC | Percutaneously implantable replacement heart valve device and method of making same |
US8840663B2 (en) | 2003-12-23 | 2014-09-23 | Sadra Medical, Inc. | Repositionable heart valve method |
US7381219B2 (en) | 2003-12-23 | 2008-06-03 | Sadra Medical, Inc. | Low profile heart valve and delivery system |
US8343213B2 (en) | 2003-12-23 | 2013-01-01 | Sadra Medical, Inc. | Leaflet engagement elements and methods for use thereof |
US11278398B2 (en) | 2003-12-23 | 2022-03-22 | Boston Scientific Scimed, Inc. | Methods and apparatus for endovascular heart valve replacement comprising tissue grasping elements |
US8052749B2 (en) | 2003-12-23 | 2011-11-08 | Sadra Medical, Inc. | Methods and apparatus for endovascular heart valve replacement comprising tissue grasping elements |
US20120041550A1 (en) | 2003-12-23 | 2012-02-16 | Sadra Medical, Inc. | Methods and Apparatus for Endovascular Heart Valve Replacement Comprising Tissue Grasping Elements |
US7988724B2 (en) | 2003-12-23 | 2011-08-02 | Sadra Medical, Inc. | Systems and methods for delivering a medical implant |
US8377110B2 (en) * | 2004-04-08 | 2013-02-19 | Endologix, Inc. | Endolumenal vascular prosthesis with neointima inhibiting polymeric sleeve |
US7465318B2 (en) * | 2004-04-15 | 2008-12-16 | Soteira, Inc. | Cement-directing orthopedic implants |
US7909873B2 (en) * | 2006-12-15 | 2011-03-22 | Soteira, Inc. | Delivery apparatus and methods for vertebrostenting |
US7794490B2 (en) * | 2004-06-22 | 2010-09-14 | Boston Scientific Scimed, Inc. | Implantable medical devices with antimicrobial and biodegradable matrices |
US7727271B2 (en) * | 2004-06-24 | 2010-06-01 | Boston Scientific Scimed, Inc. | Implantable prosthesis having reinforced attachment sites |
US7955373B2 (en) * | 2004-06-28 | 2011-06-07 | Boston Scientific Scimed, Inc. | Two-stage stent-graft and method of delivering same |
US8313524B2 (en) * | 2004-08-31 | 2012-11-20 | C. R. Bard, Inc. | Self-sealing PTFE graft with kink resistance |
US7641688B2 (en) * | 2004-09-16 | 2010-01-05 | Evera Medical, Inc. | Tissue augmentation device |
GB0422231D0 (en) * | 2004-10-07 | 2004-11-10 | Vascutek Ltd | Synthetic prosthesis |
GB0423422D0 (en) * | 2004-10-21 | 2004-11-24 | Bard Inc C R | Medical device for fluid flow, and method of forming such device |
US8029563B2 (en) * | 2004-11-29 | 2011-10-04 | Gore Enterprise Holdings, Inc. | Implantable devices with reduced needle puncture site leakage |
US7641681B2 (en) * | 2004-12-28 | 2010-01-05 | Boston Scientific Scimed, Inc. | Low profile stent-graft attachment |
US20060142852A1 (en) * | 2004-12-29 | 2006-06-29 | Boston Scientific Scimed, Inc. | Low profile, durable, reinforced ePTFE composite graft |
DE102005003632A1 (de) | 2005-01-20 | 2006-08-17 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Katheter für die transvaskuläre Implantation von Herzklappenprothesen |
JP2009501027A (ja) * | 2005-06-17 | 2009-01-15 | シー・アール・バード・インコーポレイテツド | 締付後のよじれ耐性を有する血管移植片 |
US7569071B2 (en) | 2005-09-21 | 2009-08-04 | Boston Scientific Scimed, Inc. | Venous valve, system, and method with sinus pocket |
CA2626598A1 (en) | 2005-11-09 | 2007-05-18 | C.R. Bard Inc. | Grafts and stent grafts having a radiopaque marker |
US20070213813A1 (en) | 2005-12-22 | 2007-09-13 | Symetis Sa | Stent-valves for valve replacement and associated methods and systems for surgery |
US8834912B2 (en) * | 2005-12-30 | 2014-09-16 | Boston Scientific Scimed, Inc. | Medical devices having multiple charged layers |
US20070208409A1 (en) * | 2006-03-01 | 2007-09-06 | Boston Scientific Scimed, Inc. | Flexible stent-graft devices and methods of producing the same |
US8025693B2 (en) * | 2006-03-01 | 2011-09-27 | Boston Scientific Scimed, Inc. | Stent-graft having flexible geometries and methods of producing the same |
GB0617074D0 (en) * | 2006-08-30 | 2006-10-11 | Angiomed Ag | Arteriovenous fistula |
WO2008063780A2 (en) | 2006-10-12 | 2008-05-29 | C.R. Bard Inc. | Vascular grafts with multiple channels and methods for making |
US9622888B2 (en) | 2006-11-16 | 2017-04-18 | W. L. Gore & Associates, Inc. | Stent having flexibly connected adjacent stent elements |
US7896915B2 (en) | 2007-04-13 | 2011-03-01 | Jenavalve Technology, Inc. | Medical device for treating a heart valve insufficiency |
US7498079B1 (en) * | 2007-06-13 | 2009-03-03 | Toray Fluorofibers (America), Inc. | Thermally stable polytetrafluoroethylene fiber and method of making same |
US8066755B2 (en) | 2007-09-26 | 2011-11-29 | Trivascular, Inc. | System and method of pivoted stent deployment |
US8226701B2 (en) | 2007-09-26 | 2012-07-24 | Trivascular, Inc. | Stent and delivery system for deployment thereof |
US8663309B2 (en) | 2007-09-26 | 2014-03-04 | Trivascular, Inc. | Asymmetric stent apparatus and method |
EP3245980B1 (en) | 2007-09-26 | 2022-07-20 | St. Jude Medical, LLC | Collapsible prosthetic heart valves |
US9532868B2 (en) | 2007-09-28 | 2017-01-03 | St. Jude Medical, Inc. | Collapsible-expandable prosthetic heart valves with structures for clamping native tissue |
EP2194921B1 (en) | 2007-10-04 | 2018-08-29 | TriVascular, Inc. | Modular vascular graft for low profile percutaneous delivery |
US8083789B2 (en) | 2007-11-16 | 2011-12-27 | Trivascular, Inc. | Securement assembly and method for expandable endovascular device |
US8328861B2 (en) | 2007-11-16 | 2012-12-11 | Trivascular, Inc. | Delivery system and method for bifurcated graft |
US8926688B2 (en) | 2008-01-11 | 2015-01-06 | W. L. Gore & Assoc. Inc. | Stent having adjacent elements connected by flexible webs |
ES2903231T3 (es) | 2008-02-26 | 2022-03-31 | Jenavalve Tech Inc | Stent para el posicionamiento y anclaje de una prótesis valvular en un sitio de implantación en el corazón de un paciente |
US9044318B2 (en) | 2008-02-26 | 2015-06-02 | Jenavalve Technology Gmbh | Stent for the positioning and anchoring of a valvular prosthesis |
ES2775444T3 (es) | 2008-06-06 | 2020-07-27 | Edwards Lifesciences Corp | Válvula cardíaca transcatéter de perfil bajo |
WO2009155319A1 (en) | 2008-06-17 | 2009-12-23 | Soteira, Inc. | Devices and methods for fracture reduction |
DE202009018962U1 (de) | 2008-07-15 | 2014-11-26 | St. Jude Medical, Inc. | Manschette zur Verwendung in einer Herzklappenprothese |
CN102245256B (zh) | 2008-10-10 | 2014-07-23 | 萨德拉医学公司 | 医疗装置以及用于输送医疗装置的输送系统 |
US8257640B2 (en) | 2009-08-07 | 2012-09-04 | Zeus Industrial Products, Inc. | Multilayered composite structure with electrospun layer |
US20130268062A1 (en) | 2012-04-05 | 2013-10-10 | Zeus Industrial Products, Inc. | Composite prosthetic devices |
WO2010111246A1 (en) | 2009-03-23 | 2010-09-30 | Soteira, Inc. | Devices and methods for vertebrostenting |
US20110087318A1 (en) * | 2009-10-09 | 2011-04-14 | Daugherty John R | Bifurcated highly conformable medical device branch access |
EP3028672A1 (en) | 2010-03-01 | 2016-06-08 | Colibri Heart Valve LLC | Percutaneously deliverable heart valve and method associated therewith |
AU2011257298B2 (en) | 2010-05-25 | 2014-07-31 | Jenavalve Technology Inc. | Prosthetic heart valve and transcatheter delivered endoprosthesis comprising a prosthetic heart valve and a stent |
CA2806544C (en) | 2010-06-28 | 2016-08-23 | Colibri Heart Valve Llc | Method and apparatus for the endoluminal delivery of intravascular devices |
CN106073946B (zh) | 2010-09-10 | 2022-01-04 | 西美蒂斯股份公司 | 瓣膜置换装置、用于瓣膜置换装置的递送装置以及瓣膜置换装置的生产方法 |
SG191008A1 (en) | 2010-12-14 | 2013-07-31 | Colibri Heart Valve Llc | Percutaneously deliverable heart valve including folded membrane cusps with integral leaflets |
CN109806042A (zh) * | 2011-01-28 | 2019-05-28 | 麦瑞通医疗设备有限公司 | 静电纺丝ptfe涂层支架及其使用方法 |
EP2520251A1 (en) | 2011-05-05 | 2012-11-07 | Symetis SA | Method and Apparatus for Compressing Stent-Valves |
US8945209B2 (en) | 2011-05-20 | 2015-02-03 | Edwards Lifesciences Corporation | Encapsulated heart valve |
US8968389B2 (en) | 2011-12-28 | 2015-03-03 | The Cleveland Clinic Foundation | Endoluminal prosthesis with a valve arrangement |
CN110064076A (zh) | 2012-01-16 | 2019-07-30 | 麦瑞通医疗设备有限公司 | 被旋转纺丝材料覆盖的医疗器械和制造方法 |
US8992595B2 (en) | 2012-04-04 | 2015-03-31 | Trivascular, Inc. | Durable stent graft with tapered struts and stable delivery methods and devices |
US9498363B2 (en) | 2012-04-06 | 2016-11-22 | Trivascular, Inc. | Delivery catheter for endovascular device |
US9883941B2 (en) | 2012-06-19 | 2018-02-06 | Boston Scientific Scimed, Inc. | Replacement heart valve |
US10507268B2 (en) | 2012-09-19 | 2019-12-17 | Merit Medical Systems, Inc. | Electrospun material covered medical appliances and methods of manufacture |
US9198999B2 (en) | 2012-09-21 | 2015-12-01 | Merit Medical Systems, Inc. | Drug-eluting rotational spun coatings and methods of use |
US9827703B2 (en) | 2013-03-13 | 2017-11-28 | Merit Medical Systems, Inc. | Methods, systems, and apparatuses for manufacturing rotational spun appliances |
US10799617B2 (en) | 2013-03-13 | 2020-10-13 | Merit Medical Systems, Inc. | Serially deposited fiber materials and associated devices and methods |
EP3038567B1 (en) | 2013-08-30 | 2022-09-07 | JenaValve Technology, Inc. | Radially collapsible frame for a prosthetic valve and method for manufacturing such a frame |
US9913715B2 (en) | 2013-11-06 | 2018-03-13 | St. Jude Medical, Cardiology Division, Inc. | Paravalvular leak sealing mechanism |
US9814560B2 (en) | 2013-12-05 | 2017-11-14 | W. L. Gore & Associates, Inc. | Tapered implantable device and methods for making such devices |
EP3068453B1 (en) * | 2014-02-21 | 2023-05-31 | Healionics Corporation | Vascular grafts and method for preserving patency of same |
US10154904B2 (en) | 2014-04-28 | 2018-12-18 | Edwards Lifesciences Corporation | Intravascular introducer devices |
US10195025B2 (en) | 2014-05-12 | 2019-02-05 | Edwards Lifesciences Corporation | Prosthetic heart valve |
AU2014407121B2 (en) * | 2014-09-26 | 2018-07-26 | W.L. Gore & Associates Gmbh | Process for the production of a thermally conductive article |
US10299948B2 (en) | 2014-11-26 | 2019-05-28 | W. L. Gore & Associates, Inc. | Balloon expandable endoprosthesis |
US10201417B2 (en) | 2015-02-03 | 2019-02-12 | Boston Scientific Scimed Inc. | Prosthetic heart valve having tubular seal |
DK3261589T3 (da) | 2015-02-26 | 2020-12-14 | Merit Medical Systems Inc | Lagdelte medicinske indretninger |
US10426617B2 (en) | 2015-03-06 | 2019-10-01 | Boston Scientific Scimed, Inc. | Low profile valve locking mechanism and commissure assembly |
EP3632378A1 (en) | 2015-05-01 | 2020-04-08 | JenaValve Technology, Inc. | Device and method with reduced pacemaker rate in heart valve replacement |
CN110946684B (zh) | 2015-06-05 | 2022-06-03 | W.L.戈尔及同仁股份有限公司 | 带有渐缩部的低渗血量可植入假体 |
US9974650B2 (en) | 2015-07-14 | 2018-05-22 | Edwards Lifesciences Corporation | Prosthetic heart valve |
US10179043B2 (en) | 2016-02-12 | 2019-01-15 | Edwards Lifesciences Corporation | Prosthetic heart valve having multi-level sealing member |
EP3454795B1 (en) | 2016-05-13 | 2023-01-11 | JenaValve Technology, Inc. | Heart valve prosthesis delivery system for delivery of heart valve prosthesis with introducer sheath and loading system |
US10201416B2 (en) | 2016-05-16 | 2019-02-12 | Boston Scientific Scimed, Inc. | Replacement heart valve implant with invertible leaflets |
US10568752B2 (en) | 2016-05-25 | 2020-02-25 | W. L. Gore & Associates, Inc. | Controlled endoprosthesis balloon expansion |
US11147661B2 (en) | 2016-08-08 | 2021-10-19 | W. L. Gore & Associates, Inc. | Kink resistant graft |
US10813749B2 (en) | 2016-12-20 | 2020-10-27 | Edwards Lifesciences Corporation | Docking device made with 3D woven fabric |
EP3573579B1 (en) | 2017-01-27 | 2023-12-20 | JenaValve Technology, Inc. | Heart valve mimicry |
US20210138227A1 (en) * | 2017-03-08 | 2021-05-13 | Cardiac Assist Holdings, Llc | Cardiac assist device with integrally textured membrane |
US10828154B2 (en) | 2017-06-08 | 2020-11-10 | Boston Scientific Scimed, Inc. | Heart valve implant commissure support structure |
JP2020527397A (ja) * | 2017-07-14 | 2020-09-10 | エンドーロジックス インコーポレイテッド | ステントグラフト及び熱的にひだ形成することによってステントグラフトの可撓性を高める方法 |
CN111163729B (zh) | 2017-08-01 | 2022-03-29 | 波士顿科学国际有限公司 | 医疗植入物锁定机构 |
US10939996B2 (en) | 2017-08-16 | 2021-03-09 | Boston Scientific Scimed, Inc. | Replacement heart valve commissure assembly |
WO2019051476A1 (en) | 2017-09-11 | 2019-03-14 | Incubar, LLC | SEALING DEVICE FOR USE AS A VASCULAR DUCT IMPLANT FOR REDUCING ENDOFUCTION |
WO2019144071A1 (en) | 2018-01-19 | 2019-07-25 | Boston Scientific Scimed, Inc. | Medical device delivery system with feedback loop |
EP3740160A2 (en) | 2018-01-19 | 2020-11-25 | Boston Scientific Scimed Inc. | Inductance mode deployment sensors for transcatheter valve system |
EP3749252A1 (en) | 2018-02-07 | 2020-12-16 | Boston Scientific Scimed, Inc. | Medical device delivery system with alignment feature |
WO2019165394A1 (en) | 2018-02-26 | 2019-08-29 | Boston Scientific Scimed, Inc. | Embedded radiopaque marker in adaptive seal |
EP3793478A1 (en) | 2018-05-15 | 2021-03-24 | Boston Scientific Scimed, Inc. | Replacement heart valve commissure assembly |
WO2019241477A1 (en) | 2018-06-13 | 2019-12-19 | Boston Scientific Scimed, Inc. | Replacement heart valve delivery device |
WO2020123486A1 (en) | 2018-12-10 | 2020-06-18 | Boston Scientific Scimed, Inc. | Medical device delivery system including a resistance member |
US11439504B2 (en) | 2019-05-10 | 2022-09-13 | Boston Scientific Scimed, Inc. | Replacement heart valve with improved cusp washout and reduced loading |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0666066A1 (en) * | 1994-02-08 | 1995-08-09 | Ethicon, Inc. | Bi-directional crimped graft |
US5653745A (en) * | 1991-02-28 | 1997-08-05 | Medtronic, Inc. | Prosthetic vascular graft with a pleated structure |
US5749880A (en) * | 1995-03-10 | 1998-05-12 | Impra, Inc. | Endoluminal encapsulated stent and methods of manufacture and endoluminal delivery |
US20010049553A1 (en) * | 1998-05-08 | 2001-12-06 | Allan Ratner | Prosthetic tublar aortic condit and method for manufacturing the same |
EP1212988A2 (en) * | 2000-11-16 | 2002-06-12 | Cordis Corporation | A stent graft having a pleated graft member |
WO2002100454A1 (en) * | 2001-06-11 | 2002-12-19 | Boston Scientific Limited | COMPOSITE ePTFE/TEXTILE PROSTHESIS |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4082893A (en) * | 1975-12-24 | 1978-04-04 | Sumitomo Electric Industries, Ltd. | Porous polytetrafluoroethylene tubings and process of producing them |
DE3019996A1 (de) * | 1980-05-24 | 1981-12-03 | Institute für Textil- und Faserforschung Stuttgart, 7410 Reutlingen | Hohlorgan |
US5549860A (en) * | 1989-10-18 | 1996-08-27 | Polymedica Industries, Inc. | Method of forming a vascular prosthesis |
US5123917A (en) * | 1990-04-27 | 1992-06-23 | Lee Peter Y | Expandable intraluminal vascular graft |
CA2038605C (en) * | 1990-06-15 | 2000-06-27 | Leonard Pinchuk | Crack-resistant polycarbonate urethane polymer prostheses and the like |
US5229431A (en) * | 1990-06-15 | 1993-07-20 | Corvita Corporation | Crack-resistant polycarbonate urethane polymer prostheses and the like |
US5735892A (en) * | 1993-08-18 | 1998-04-07 | W. L. Gore & Associates, Inc. | Intraluminal stent graft |
US5723004A (en) * | 1993-10-21 | 1998-03-03 | Corvita Corporation | Expandable supportive endoluminal grafts |
CA2188563C (en) * | 1994-04-29 | 2005-08-02 | Andrew W. Buirge | Stent with collagen |
US5665114A (en) | 1994-08-12 | 1997-09-09 | Meadox Medicals, Inc. | Tubular expanded polytetrafluoroethylene implantable prostheses |
US6264684B1 (en) * | 1995-03-10 | 2001-07-24 | Impra, Inc., A Subsidiary Of C.R. Bard, Inc. | Helically supported graft |
US5664114A (en) * | 1995-05-16 | 1997-09-02 | Hewlett-Packard Company | Asynchronous FIFO queuing system operating with minimal queue status |
US5609629A (en) * | 1995-06-07 | 1997-03-11 | Med Institute, Inc. | Coated implantable medical device |
EP0830110B2 (en) * | 1995-06-07 | 2010-08-04 | Edwards Lifesciences Corporation | Externally supported tape reinforced vascular graft |
US5628788A (en) * | 1995-11-07 | 1997-05-13 | Corvita Corporation | Self-expanding endoluminal stent-graft |
US5788626A (en) * | 1995-11-21 | 1998-08-04 | Schneider (Usa) Inc | Method of making a stent-graft covered with expanded polytetrafluoroethylene |
US6428571B1 (en) * | 1996-01-22 | 2002-08-06 | Scimed Life Systems, Inc. | Self-sealing PTFE vascular graft and manufacturing methods |
US5800512A (en) * | 1996-01-22 | 1998-09-01 | Meadox Medicals, Inc. | PTFE vascular graft |
US5607478A (en) * | 1996-03-14 | 1997-03-04 | Meadox Medicals Inc. | Yarn wrapped PTFE tubular prosthesis |
US5928279A (en) * | 1996-07-03 | 1999-07-27 | Baxter International Inc. | Stented, radially expandable, tubular PTFE grafts |
US6517571B1 (en) | 1999-01-22 | 2003-02-11 | Gore Enterprise Holdings, Inc. | Vascular graft with improved flow surfaces |
US6440166B1 (en) * | 1999-02-16 | 2002-08-27 | Omprakash S. Kolluri | Multilayer and multifunction vascular graft |
US6364903B2 (en) * | 1999-03-19 | 2002-04-02 | Meadox Medicals, Inc. | Polymer coated stent |
US6312457B1 (en) * | 1999-04-01 | 2001-11-06 | Boston Scientific Corporation | Intraluminal lining |
US6368347B1 (en) * | 1999-04-23 | 2002-04-09 | Sulzer Vascutek Ltd. | Expanded polytetrafluoroethylene vascular graft with coating |
US7597775B2 (en) | 2001-10-30 | 2009-10-06 | Boston Scientific Scimed, Inc. | Green fluoropolymer tube and endovascular prosthesis formed using same |
US6814561B2 (en) | 2001-10-30 | 2004-11-09 | Scimed Life Systems, Inc. | Apparatus and method for extrusion of thin-walled tubes |
-
2003
- 2003-08-19 US US10/643,315 patent/US7510571B2/en not_active Expired - Fee Related
-
2004
- 2004-08-19 EP EP20040781710 patent/EP1663067A1/en not_active Withdrawn
- 2004-08-19 WO PCT/US2004/027084 patent/WO2005018502A1/en active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5653745A (en) * | 1991-02-28 | 1997-08-05 | Medtronic, Inc. | Prosthetic vascular graft with a pleated structure |
EP0666066A1 (en) * | 1994-02-08 | 1995-08-09 | Ethicon, Inc. | Bi-directional crimped graft |
US5749880A (en) * | 1995-03-10 | 1998-05-12 | Impra, Inc. | Endoluminal encapsulated stent and methods of manufacture and endoluminal delivery |
US20010049553A1 (en) * | 1998-05-08 | 2001-12-06 | Allan Ratner | Prosthetic tublar aortic condit and method for manufacturing the same |
EP1212988A2 (en) * | 2000-11-16 | 2002-06-12 | Cordis Corporation | A stent graft having a pleated graft member |
WO2002100454A1 (en) * | 2001-06-11 | 2002-12-19 | Boston Scientific Limited | COMPOSITE ePTFE/TEXTILE PROSTHESIS |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2429407B (en) * | 2005-06-04 | 2009-10-14 | Vascutek Ltd | Thin-walled vascular graft |
US7901446B2 (en) | 2005-06-04 | 2011-03-08 | Vascutek Limited | Thin-walled vascular graft |
WO2007002331A1 (en) * | 2005-06-23 | 2007-01-04 | Boston Scientific Scimed, Inc. | Eptfe lamination-resizing eptfe tubing |
JP2008543507A (ja) * | 2005-06-23 | 2008-12-04 | ボストン サイエンティフィック リミテッド | ePTFE積層−ePTFE管の再サイジング |
US7963988B2 (en) | 2005-06-23 | 2011-06-21 | Boston Scientific Scimed, Inc. | ePTFE lamination—resizing ePTFE tubing |
DE102007008185A1 (de) * | 2007-02-13 | 2008-08-14 | Aesculap Ag & Co. Kg | Non woven Gefäßprothese und Verfahren zu ihrer Herstellung |
WO2011146733A1 (en) | 2010-05-20 | 2011-11-24 | Maquet Cardiovascular Llc | Composite prosthesis with external polymeric support structure and methods of manufacturing the same |
US8696738B2 (en) | 2010-05-20 | 2014-04-15 | Maquet Cardiovascular Llc | Composite prosthesis with external polymeric support structure and methods of manufacturing the same |
US9375326B2 (en) | 2010-05-20 | 2016-06-28 | Maquet Cardiovascular Llc | Composite prosthesis with external polymeric support structure and methods of manufacturing the same |
EP3141214A1 (en) * | 2010-05-20 | 2017-03-15 | Maquet Cardiovascular LLC | Composite prosthesis with external polymeric support structure and methods of manufacturing the same |
US9956069B2 (en) | 2010-05-20 | 2018-05-01 | Maquet Cardiovascular Llc | Composite prosthesis with external polymeric support structure and methods of manufacturing the same |
US20210260252A1 (en) * | 2011-10-07 | 2021-08-26 | W. L. Gore & Associates, Inc. | Puncturable and resealable graft |
CN115252900A (zh) * | 2017-10-31 | 2022-11-01 | 豪淘斯医疗有限公司 | 具有密封剂或覆层的纺织产品和制造方法 |
Also Published As
Publication number | Publication date |
---|---|
US20040033364A1 (en) | 2004-02-19 |
EP1663067A1 (en) | 2006-06-07 |
US7510571B2 (en) | 2009-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7510571B2 (en) | Pleated composite ePTFE/textile hybrid covering | |
US7828833B2 (en) | Composite ePTFE/textile prosthesis | |
CA2554631C (en) | Pressure lamination method for forming composite eptfe/textile and eptfe/stent/textile prostheses | |
EP1794248B1 (en) | Elastomeric radiopaque adhesive composite and prosthesis | |
US7727271B2 (en) | Implantable prosthesis having reinforced attachment sites | |
CA2450160C (en) | Composite eptfe/textile prosthesis | |
AU783826B2 (en) | Spider silk covered stent | |
EP0689805B1 (en) | Bistable luminal graft endoprostheses | |
EP2661286B1 (en) | A stent graft with double eptfe-layered-system with high plasticity and high rigidity | |
EP1845893B1 (en) | Low profile stent-graft attachment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004781710 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004781710 Country of ref document: EP |